Vifor Pharma Ltd, AMAG Pharmaceuticals Inc. and Fresenius SE & Co. KGaA are dominating the Global Iron-Deficiency Anemia Therapy Market in 2019

Global Iron-Deficiency Anemia Therapy Market is expected to grow with the CAGR of 16.4% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.

Access Full Report at https://www.databridgemarketresearch.com/reports/global-iron-deficiency-anemia-therapy-market

Global iron-deficiency anemia therapy market is a highly consolidated market, which includes specific number of key players as well as local players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in global iron-deficiency anemia therapy market are introducing strong range of product portfolio. This helped companies to maximize the sales with enhanced product portfolio.

  • For instance, in July 2019, Vifor Pharma Ltd. announced the expected launch Ferinject in Japan by the end of 2019. This action by Vifor Pharma Ltd. has increased its credibility in the market and will increase its sales and revenue in future with market expansion. Vifor Pharma Ltd is the dominating global iron-deficiency anemia Therapy Market.

The other key players existing in the market includes AMAG Pharmaceuticals, Fresenius SE & CO. KGAA, Sanofi, Novartis AG, Abbvie INC., Akebia Therapeutics, INC., CHO-A PHARMACEUTICAL CO., LTD., Lupin, Orion Corporation, PHARMACOSMOS A/S, Shield Therapeutics, Teva Pharmaceutical Industries LTD., Zydus Cadila, Advanz Pharmaceutical, Rockwell Medical, GlaxoSmithKline plc., Alkem Labs, Hikma Pharmaceuticals PLC, Avion Pharmaceuticals, LLC  among others.

Iron-Deficiency Anemia Therapy Market

Vifor Pharma Ltd

Vifor Pharma Ltd, founded in 1872, headquartered in Zurich, Switzerland. The company focuses on developing, production and marketing of nephrology, iron deficiency and cardio-renal therapies in order to help patients around the world with chronic diseases to lead healthier lives. The business segments of the company includes ferinject/injectafer, venofer, maltofer, mircera, retacritvelphoro, veltassa, other rx brands, anti-infectivesand third party production out of which the market focused segments are ferinject/injectafer, venoferand maltofer. The company is providing products in iron, phosphate binder, potassium binder and infectious disease/ OTX as product categories. The company is engaged in continues development of Iron-deficiency anemia product portfolio in the global Iron-deficiency anemia therapy market.

For Instance, 

  • Vifor Pharma Ltd. announced in July that its iron deficiency anaemia product, called Ferinject, is scheduled to be released in Japan by the end of 2019, subject to reimbursement for the procurement. Such move by Vifor Pharma Ltd. has improved its business reputation and, with market growth, will boost its profits and revenues in the future.

The company has wide global presence across the globe such as North America, Europe and  Asia-Pacific. In addition to it, the company also generates its revenue from the various subsidiary companies such as ViforLtd (Switzerland), Relypsa, Inc (United States), ViforPharma BelgiëNV (Belgium), ViforFrance S.A.S. (France) and OM Pharma, S.A (Portugal) among others.

AMAG Pharmaceuticals:

AMAG Pharmaceuticals, headquartered in Massachusetts, U.S. The company focuses on developing and delivering innovative medicines for complex and under-treated health conditions for therapeutic areas including anemia, pregnancy complications, women’s sexual function and menopause-related issues. The company is engaged in continues development of Iron-deficiency anemia product portfolio in the global iron-deficiency anemia therapy market.

For Instance,

  •  In December 2018, Amag Pharmaceuticals, Inc., announced the positive result of the study of Feraheme in fatigue and quality of life in iron deficiency anemia patients in the study namely, Sustained Improvements in Fatigue and Quality of Life in Iron Deficiency Anemia Patients This helped Amag Pharmaceuticals, Inc. to gain credibility in the market.

The company has global presence in the U.S and its various subsidiaries inludes Perosphere Inc. (U.S.), Ther-Rx (U.S.),  Amag Pharma USA, Inc. (U.S.), CBR Systems, Inc. (U.S.)and snowbird, Inc. (U.S.) among others.

Fresenius SE & Co. KGaA :

Fresenius SE & Co. KGaA, headquartered in BadHomburg, Germany which was founded in 1912. The company focuses on providing high-quality products and services for dialysis, hospitals, and outpatient treatment. The company is engaged in continues development of iron-deficiency anemia product portfolio in the global iron-deficiency anemia therapy market.

The company has wide global presence in North America, Europe, South America, Middle East & Africa, and Asia-Pacific. In addition to it, the company also generates its revenue from the various subsidiary companies such as Fresenius Kabi Singapore PteLtd.(Singapore), Fresenius Kabi India Pvt.Ltd. (India), Fresenius Kabi USA, LLC (U.S.), Fresenius Kabi GroupeFrance(France), Fresenius Kabi México, S.A. de C.V. (Mexico), among others.